KAPA
Kairos Pharma, LTD.
$0.4500
+2.27%
$9.2M
No data for this timeframe.
Vol
Market Cap$9.2M
Cap SizeNano Cap
Inst. Holders3 funds
Inst. Value$160.4K
Inst. Activity1 buys / 1 sells
SEC Reports3
Recent Activity
Jun 4, 2026
SEC
Kairos Pharma issued a mid-year shareholder letter announcing a term sheet to acquire worldwide rights to CL-741, a Phas
8-K — Impact 4/10
May 26, 2026
SEC
Kairos Pharma filed a DEFA14A supplement correcting the record date for its 2026 Annual Meeting from May 15 to May 18, 2
DEFA14A — Impact 2/10
Feb 26, 2026
SEC
Kairos Pharma (KAPA) announced a letter of intent to acquire worldwide rights to two clinical-stage oncology assets, CL-
8-K — Impact 7/10
Inst.
TWO SIGMA INVESTMENTS, LP — DOUBLED
94,008 shares ($66.7K)
Inst.
BANK OF AMERICA CORP — TRIM
134 shares ($95.00)
Price Targets
Historical data — last covering-analyst action Nov 2025. No current recommendation available.
$8.00 (Nov 2025)
Current $0.4310
Low $4.00
Median $8.00
High $12.00
2 analysts
$4.00
$12.00
Analyst Ratings
2Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Nov 19, 2025 | D. Boral Capital | MAINTAIN | Buy → Buy |
| Nov 4, 2025 | D. Boral Capital | MAINTAIN | Buy → Buy |
| Oct 20, 2025 | D. Boral Capital | MAINTAIN | Buy → Buy |
| Oct 7, 2025 | D. Boral Capital | MAINTAIN | Buy → Buy |
| Sep 19, 2025 | D. Boral Capital | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.09 ▼ -12.5% | $-0.09 — $-0.09 | -13% YoY | 1 |
| Next Q | $-0.09 | $-0.09 — $-0.09 | -29% YoY | 1 |
| Current FY | $-0.37 ▲ +2.6% | $-0.37 — $-0.37 | -23% YoY | 1 |
| Next FY | $-0.67 ▼ -22.9% | $-0.67 — $-0.67 | -81% YoY | 1 |
Latest Reports
NEUTRAL
8-K
4/10
Kairos Pharma issued a mid-year shareholder letter announcing a term sheet to acquire worldwide rights to CL-741, a Phas
Jun 4, 2026
NEUTRAL
DEFA14A
2/10
Kairos Pharma filed a DEFA14A supplement correcting the record date for its 2026 Annual Meeting from May 15 to May 18, 2
May 26, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $93.6K | NEW |
| TWO SIGMA INVESTMENTS, LP | $66.7K | DOUBLED |
| BANK OF AMERICA CORP | $95.00 | TRIM |
3 institutional holders with $160.4K total value (225,970 shares) as of 2025-Q4. Top holders: VANGUARD, TWO, BANK.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 131,828 | $93.6K | 58.3% | NEW |
| 2 | TWO SIGMA INVESTMENTS, LP | 94,008 | $66.7K | 41.6% | DOUBLED +105.3% |
| 3 | BANK OF AMERICA CORP /DE/ | 134 | $95.00 | 0.1% | TRIM -55.9% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 45,789 | 94,008 | +105.3% | $66.7K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 304 | 134 | -55.9% | $95.00 | 2025-Q4 |
| VANGUARD GROUP INC | NEW | — | 131,828 | — | $154.2K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 45,789 | — | $53.6K | 2025-Q3 |
| UBS Group AG | TRIM | 9,458 | 5,979 | -36.8% | $7.0K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 51 | 304 | +496.1% | $356.00 | 2025-Q3 |
| UBS Group AG | DOUBLED | 2,792 | 9,458 | +238.8% | $6.7K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 21 | 51 | +142.9% | $36.00 | 2025-Q2 |
| UBS Group AG | TRIM | 10,845 | 2,792 | -74.3% | $2.6K | 2025-Q1 |
| CITADEL ADVISORS LLC | NEW | — | 10,969 | — | $16.7K | 2024-Q4 |
| UBS Group AG | NEW | — | 10,845 | — | $16.5K | 2024-Q4 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
3 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 4.3/10.
NEUTRAL
8-K
4/10
Kairos Pharma issued a mid-year shareholder letter announcing a term sheet to acquire worldwide righ
Jun 4, 2026
NEUTRAL
DEFA14A
2/10
Kairos Pharma filed a DEFA14A supplement correcting the record date for its 2026 Annual Meeting from
May 26, 2026
BULLISH
8-K
7/10
Kairos Pharma (KAPA) announced a letter of intent to acquire worldwide rights to two clinical-stage
Feb 26, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Nov 2025): 88% buy across 8 analysts — 2 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Nov 2025. No current recommendation available.
$8.00 mean target (Nov 2025)
$4.00 Low
$12.00 High
| Metric | Value |
|---|---|
| Current Price | $0.4310 |
| Target Low | $4.00 |
| Target Mean | $8.00 |
| Target Median | $8.00 |
| Target High | $12.00 |
| # Analysts | 2 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.09 | $-0.09 | $-0.09 | -12.5% | -12.5% | — | $0.0B | 0.0% | 1 |
| Next Q 2026-09-30 |
$-0.09 | $-0.09 | $-0.09 | -28.6% | +0.0% | — | $0.0B | 0.0% | 1 |
| Current FY 2026-12-31 |
$-0.37 | $-0.37 | $-0.37 | -23.3% | +2.6% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Next FY 2027-12-31 |
$-0.67 | $-0.67 | $-0.67 | -81.1% | -22.9% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.090 | |
| 7d ago | $-0.080 | -0.010 |
| 30d ago | $-0.080 | -0.010 |
| 60d ago | $0.000 | -0.090 |
| 90d ago | $0.000 | -0.090 |
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 3 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Nov 19, 2025 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Nov 4, 2025 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Oct 20, 2025 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Oct 7, 2025 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Sep 19, 2025 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Jul 16, 2025 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Jun 4, 2025 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Apr 17, 2025 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Apr 3, 2025 | HC Wainwright & Co. | INITIATE | — | Buy |
| Mar 31, 2025 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 27, 2025 | Maxim Group | INITIATE | — | Buy |
| Mar 20, 2025 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Feb 26, 2025 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Feb 18, 2025 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Feb 12, 2025 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Jan 22, 2025 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Nov 14, 2024 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Oct 14, 2024 | EF Hutton | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Apr 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Mar 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Feb 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Jan 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.